Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (24 quarters reported)
$164M in Q4 2013 → $45.3M now. Hover for any quarter.
As reported for the quarter ended September 30, 2019. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| AT Aimmune Therapeutics Inc. | 57.3% | Trimmed 38% | 1,240,000 | $26M |
| Adma Biologics Inc | 35.5% | Unchanged | 3,608,171 | $16.1M |
| Cidara Therapeutics Inc. | 3.9% | Trimmed 13% | 891,614 | $1.78M |
| T Transenterix Inc. | 3.3% | Unchanged | 2,389,352 | $1.48M |
| Viewray Inc. | 0.0% | New | 18,964 | — |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2019 · filed November 13, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AT Aimmune Therapeutics Inc. | Trimmed | −750,000 | −$15.7M | 57.3% |
| Cidara Therapeutics Inc. | Trimmed | −129,534 | −$258K | 3.9% |
| Viewray Inc. | New | +18,964 | — | — |
quarter ended June 30, 2019 · filed August 08, 2019
No position changes this quarter.
quarter ended March 31, 2019 · filed May 07, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| LO Loxo Oncology Inc | Exited | −2,038,920 | −$286M | — |
| Viewray Inc. | Exited | −363,640 | −$2.21M | — |
| Chimerix Inc. | Exited | −472,943 | −$1.22M | — |
| PT Pernix Therapeutics Hldgs In | Exited | −210,000 | −$88K | — |
| PT Pernix Therapeutics Hldgs Inc | Exited | −2,500,000 | −$16K | — |
quarter ended December 31, 2018 · filed February 11, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Viewray Inc. | Trimmed | −1,372,348 | −$8.33M | 0.6% |
quarter ended September 30, 2018 · filed November 05, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| LO Loxo Oncology Inc | Trimmed | −1,400,000 | −$239M | 75.3% |
| Viewray Inc. | Trimmed | −5,744,899 | −$53.8M | 3.5% |
| T Transenterix Inc. | Trimmed | −4,000,000 | −$23.2M | 3.0% |
| AT Aimmune Therapeutics Inc. | Trimmed | −250,000 | −$6.82M | 11.7% |
quarter ended June 30, 2018 · filed August 13, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| T Transenterix Inc. | Trimmed | −3,500,000 | −$15.3M | 3.7% |
| Agile Therapeutics Inc. | Exited | −1,304,933 | −$3.35M | — |
quarter ended March 31, 2018 · filed May 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| EM Entellus Med Inc | Exited | −528,655 | −$12.9M | — |
| Syros Pharmaceuticals, Inc. | Exited | −508,565 | −$4.95M | — |
quarter ended December 31, 2017 · filed February 07, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| LO Loxo Oncology Inc | Trimmed | −750,000 | −$63.1M | 57.2% |
| ET Esperion Therapeutics Inc Ne | Exited | −837,125 | −$42M | — |
| AT Aimmune Therapeutics Inc. | Trimmed | −750,000 | −$28.4M | 16.7% |
| Agile Therapeutics Inc | Trimmed | −500,000 | −$1.34M | 0.7% |
| T Transenterix Inc. | Trimmed | −446,467 | −$862K | 3.8% |
| ZA Zeltiq Aesthetics Inc | Exited | −11,985 | — | — |
Loading...
